| 前收盘价格 | 0.990 |
| 收盘价格 | 0.985 |
| 成交量 | 4,211 |
| 平均成交量 (3个月) | 242,214 |
| 市值 | 169,290,096 |
| 市盈率 (P/E TTM) | 19.60 |
| 预期市盈率 (P/E Forward) | 22.47 |
| 价格/销量 (P/S) | 2.55 |
| 股市价格/股市净资产 (P/B) | 2.70 |
| 52周波幅 | |
| 利润日期 | 22 Aug 2024 |
| 营业毛利率 | 12.55% |
| 营业利益率 (TTM) | 19.73% |
| 稀释每股收益 (EPS TTM) | 0.050 |
| 季度收入增长率 (YOY) | 11.30% |
| 季度盈利增长率 (YOY) | -1.80% |
| 总债务/股东权益 (D/E MRQ) | 1.64% |
| 流动比率 (MRQ) | 3.45 |
| 营业现金流 (OCF TTM) | 5.78 M |
| 杠杆自由现金流 (LFCF TTM) | 2.50 M |
| 资产报酬率 (ROA TTM) | 6.89% |
| 股东权益报酬率 (ROE TTM) | 13.87% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Health Information Services (AU) | 混合的 | 混合的 |
| Health Information Services (全球的) | 混合的 | 看跌 | |
| 股票 | COGSTATE FPO [CGS] | - | - |
AIStockmoo 评分
| 分析师共识 | 0.0 |
| 内部交易活动 | NA |
| 价格波动 | 4.5 |
| 技术平均移动指标 | -2.5 |
| 技术振荡指标 | 3.5 |
| 平均 | 1.38 |
|
Cogstate Ltd is a cognitive science company. The principal activity of the group is Creation, validation and commercialisation of digital brain health assessments; and Design and provision of quality assurance services in clinical trials, focused on the administration, scoring and recording of conventional brain health assessments and reporting. Its operating segment includes Clinical Trials; Healthcare and Research. The company generates maximum revenue from the Clinical Trials segment. In the clinical trials segment, technology and services are sold to pharmaceutical and biotechnology companies. The company derives revenue from the sale of licensed software and cognitive testing services. |
|
| 部门 | Healthcare |
| 行业 | Health Information Services |
| 投资方式 | Small Growth |
| 内部持股比例 | 42.23% |
| 机构持股比例 | 22.22% |
该时间范围内无数据。
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合